for vascular stabilization
Aerpio Pharmaceuticals is a biopharmaceutical company focused on leveraging Tie2 activation for ocular disease and vascular stabilization.
Our lead product candidate, razuprotafib (AKB-9778), is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open angle glaucoma. A Phase 2 trial in patients with open angle glaucoma/ocular hypertension is ongoing with top line data anticipated in Q4 2020.
The vascular stabilizing effects of subcutaneously administered razuprotafib are being investigated in two Phase 2 trials in patients with COIVD-19 (I-SPY-COVID-19 and RESCUE) which will read out in 2021.
The Company is also evaluating development options for subcutaneously administered razuprotafib and ARP- 1536, a humanized Tie2-activating monoclonal antibody, in the treatment of diabetic vascular complications including nephropathy.
ARP-1536 is also in preclinical development for intravitreal administration as an adjunct to anti-VEGF therapy in patients with sight threatening retinopathies i.e. diabetic macular edema (DME) and wet age-related macular degeneration (wetAMD).
The Company’s third asset is a bispecific antibody that is designed to inhibit VEGF and activate Tie2. This bispecific antibody has the potential to be an improved treatment for DME and wet age-related macular degeneration via intravitreal injection and cancer via systemic administration.
Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class orally bioavailable, gut targeted small molecule hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor. GB004 is being developed by AKB-4924’s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS), in return for upfront payments totaling $35 million, future potential development, regulatory, and sales milestones of up to $90 million, and royalties on worldwide net sales.
Press Releases
Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Earnings
Ended fourth quarter 2020 with $42.6 million in cash and cash equivalents Aerpio is currently evaluating a range of strategic alternatives focused on ...
Mar 11, 2021
SAN FRANCISCO and CINCINNATI , March 05, 2021 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, ...
Mar 05, 2021
Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial
Earnings
CINCINNATI , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical co ...
Jan 05, 2021
Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial
Earnings
Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group. Patient enrollment and dosing continues i ...
Dec 11, 2020
Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early ...
Nov 10, 2020
Call Taking Place on Thursday, November 12th @ 11amET CINCINNATI , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ...
Nov 05, 2020
CINCINNATI , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ...
Nov 05, 2020
The trial in moderate-to-severe patients is Aerpio’s second clinical trial in COVID-19 patients and is funded in part by the U . S . military The mi ...
Oct 26, 2020
Topline Data Expected 4Q 2020 CINCINNATI , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO), a biopharmaceuti ...
Sep 15, 2020
SAN FRANCISCO and CINCINNATI, Sept. 1, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals , Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap He ...
Sep 01, 2020
Initiated a Phase 2 Open Angle Glaucoma Trial; Recruiting Ahead of Schedule Announced Partnership with I-SPY to Participate in a Clinical Trial to Tre ...
Aug 12, 2020
CINCINNATI , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ...
Aug 10, 2020
CINCINNATI , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through th ...
Aug 04, 2020
CINCINNATI , June 24, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ...
Jun 24, 2020
Jun 12, 2020
CINCINNATI , June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the publi ...
Jun 08, 2020
CINCINNATI , June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ...
Jun 08, 2020
SAN FRANCISCO and CINCINNATI , May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare C ...
May 27, 2020
Aerpio Received an Immediate Payment of $15 million CINCINNATI , May 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ...
May 12, 2020
Razuprotafib (formerly known as AKB-9778) Phase 2 Open Angle Glaucoma Trial on Track for Third Quarter Start CINCINNATI , May 07, 2020 (GLOBE NEWSWIR ...
May 07, 2020
Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Earnings
Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 20 ...
Mar 16, 2020
CINCINNATI , March 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compoun ...
Mar 12, 2020
Data presented at the 9 th Annual Glaucoma 360 New Horizons Forum CINCINNATI --(BUSINESS WIRE)--Feb. 7, 2020-- Aerpio Pharmaceuticals, Inc. (Nasdaq: A ...
Feb 07, 2020
CINCINNATI --(BUSINESS WIRE)--Jan. 8, 2020-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...
Jan 08, 2020
CINCINNATI --(BUSINESS WIRE)--Nov. 7, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...
Nov 07, 2019
CINCINNATI --(BUSINESS WIRE)--Oct. 21, 2019-- Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compoun ...
Oct 21, 2019
CINCINNATI --(BUSINESS WIRE)--Oct. 10, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compoun ...
Oct 10, 2019
CINCINNATI --(BUSINESS WIRE)--Aug. 8, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...
Aug 08, 2019
CINCINNATI --(BUSINESS WIRE)--Jun. 10, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...
Jun 10, 2019
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Quarter of 2 ...
May 09, 2019
Data presented during “The Role of the Tie2 Pathway in Ocular Disease” symposium at the Association for Research in Vision and Ophthalmology (ARVO ...
May 02, 2019
Data to be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting CINCINNATI --(BUSINESS WIRE)--Apr. 25, 201 ...
Apr 25, 2019
CINCINNATI --(BUSINESS WIRE)--Apr. 5, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...
Apr 05, 2019
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
Earnings
TIME-2b Study Did Not Meet the Primary Endpoint of 2-Step Reduction in DRSS Score Conference Call and Webcast Today, March 18th at 8:30 a.m. EDT CINCI ...
Mar 18, 2019
Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Earnings
Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) Expe ...
Mar 05, 2019
CINCINNATI --(BUSINESS WIRE)--Feb. 26, 2019-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds ...
Feb 26, 2019
CINCINNATI --(BUSINESS WIRE)--Jan. 17, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...
Jan 17, 2019
CINCINNATI --(BUSINESS WIRE)--Nov. 8, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ...
Nov 08, 2018
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track Conference Call and Webcast Today, November 7 th at 8:30 a.m. EST CI ...
Nov 07, 2018
CINCINNATI --(BUSINESS WIRE)--Oct. 31, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds ...
Oct 31, 2018
CINCINNATI --(BUSINESS WIRE)--Oct. 25, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...
Oct 25, 2018
CINCINNATI --(BUSINESS WIRE)--Sep. 24, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...
Sep 24, 2018
CINCINNATI --(BUSINESS WIRE)--Aug. 30, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...
Aug 30, 2018
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track; Data in Q2 2019 Partnership for AKB-4924 with Gossamer Bio ...
Aug 14, 2018
CINCINNATI --(BUSINESS WIRE)--Aug. 7, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on advancing first-in-cla ...
Aug 07, 2018
CINCINNATI --(BUSINESS WIRE)--Jun. 26, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that its common stock will begi ...
Jun 26, 2018
CINCINNATI --(BUSINESS WIRE)--Jun. 25, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that it intends to sell, subjec ...
Jun 25, 2018
CINCINNATI & SAN DIEGO --(BUSINESS WIRE)--Jun. 25, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced an exclusive global license a ...
Jun 25, 2018
CINCINNATI --(BUSINESS WIRE)--May 31, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-clas ...
May 31, 2018
CINCINNATI --(BUSINESS WIRE)--May 22, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multip ...
May 22, 2018
Aerpio Pharmaceuticals Announces Nomination of Industry Veteran Cheryl Cohen to Board of Directors
General
CINCINNATI --(BUSINESS WIRE)--May 15, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-clas ...
May 15, 2018
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track CINCINNATI --(BUSINESS WIRE)--May 15, 2018-- Aerpio Pharmace ...
May 15, 2018
CINCINNATI --(BUSINESS WIRE)--May 4, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class ...
May 04, 2018
CINCINNATI --(BUSINESS WIRE)--Mar. 20, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in- ...
Mar 20, 2018
CINCINNATI --(BUSINESS WIRE)--Mar. 15, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in- ...
Mar 15, 2018
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Earnings
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call and Webcast Today, March 13 th at 8:30 a.m. ...
Mar 13, 2018
CINCINNATI --(BUSINESS WIRE)--Mar. 7, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-cl ...
Mar 07, 2018
CINCINNATI --(BUSINESS WIRE)--Mar. 6, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-c ...
Mar 06, 2018
CINCINNATI --(BUSINESS WIRE)--Feb. 28, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-cla ...
Feb 28, 2018
CINCINNATI --(BUSINESS WIRE)--Feb. 9, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB:ARPO) (“ Aerpio ”), a biopharmaceutical company focused on adva ...
Feb 09, 2018
CINCINNATI --(BUSINESS WIRE)--Dec. 18, 2017-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO) (“ Aerpio ”), a biopharmaceutical company focused on ad ...
Dec 18, 2017
CINCINNATI --(BUSINESS WIRE)--Nov. 14, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-cl ...
Nov 14, 2017
Strengthened Senior Leadership Team with the Appointment of Stephen Hoffman , M.D., Ph.D., as Chief Executive Officer Effective December 1, 2017 TIME- ...
Nov 13, 2017
CINCINNATI --(BUSINESS WIRE)--Oct. 10, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-cl ...
Oct 10, 2017
Commenced Trading on the OTCQB ® Market Continue to Dose Patients in the TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy CIN ...
Aug 14, 2017
Aug 08, 2017
Jun 29, 2017
Mar 29, 2017
Mar 16, 2017
Mar 15, 2017
Mar 08, 2017
Feb 10, 2016
Nov 17, 2015
Oct 07, 2015
Jul 15, 2015
Dec 04, 2014
Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases
General
Sep 02, 2014
May 05, 2014
Apr 23, 2014
Apr 07, 2014
Feb 13, 2014
Nov 06, 2013
Aug 05, 2013
Aerpio Therapeutics is proud to be an event sponsor for the upcoming 2012 annual NAVBO meeting
General
Sep 21, 2012
Sep 19, 2012
Aug 30, 2012
Aug 22, 2012
May 10, 2012
Mar 20, 2012
About Aerpio